Amgen | AMGN - Current Assets


Amgen reported $31.48B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
ALKERMES USD 1.52B 164.26M Jun/2026
Amgen USD 31.48B 2.42B Mar/2026
Biogen USD 7.31B 1.88B Jun/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
Exelixis USD 1.21B 234.65M Mar/2026
Genmab DKK 2.88B 1.59B Dec/2025
Gilead Sciences USD 18.64B 1.25B Mar/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Glaxosmithkline GBP 17.76B 5.83B Mar/2026
Incyte USD 6.03B 542.31M Jun/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
J&J USD 59.77B 601M Jun/2026
Merck USD 35.02B 8.5B Mar/2026
Moderna USD 5.82B 45M Jun/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Novartis USD 27.35B 744M Jun/2026
Novartis USD 26.61B 3.85B Mar/2026
Pfizer USD 42.82B 76M Mar/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 31.52B 1.36B Jun/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Takeda JPY 3.15T 59.77B Jun/2026
Teva Pharmaceutical Industries USD 13.76B 50M Jun/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026